{"product_id":"rigel-swot-analysis","title":"Rigel Pharmaceuticals SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Company’s Strategic Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eRigel Pharmaceuticals shows promising R\u0026amp;D momentum with niche immunology and oncology assets, but faces commercial scale challenges and patent cliffs; regulatory outcomes and partnerships will be decisive. Discover the complete picture behind the company’s market position with our full SWOT analysis—an investor-ready, editable report that equips you to evaluate risks, spot opportunities, and plan strategy with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Product Revenue Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRigel Pharmaceuticals reported record 2025 net product sales of ~$232 million, up ~60% year-over-year, driven by strong demand for its three FDA-approved therapies Tavalisse (fostamatinib), Rezlidhia (reversional?), and Gavreto (pralsetinib).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified Commercial Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRigel moved from one-drug status to a commercial biotech with three revenue drugs: Tavalisse (chronic immune thrombocytopenia, \u0026gt;$210m 2024 net sales), Rezlidhia (AML launches, $45m 2024 sales), and Gavreto (RET fusion-positive lung cancer, acquired 2024, $380m pro forma 2024 sales), cutting single-product risk and broadening high-value oncology and hematology revenue streams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSustained Profitability and Cash Position\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBy end-2025 Rigel Pharmaceuticals sustained positive net income for the year, a rare outcome for a mid-cap biotech showing financial maturity.\u003c\/p\u003e\n\u003cp\u003eThe company generated about $77 million cash from operations in 2025 and closed the year with roughly $154.6 million in cash and short-term investments.\u003c\/p\u003e\n\u003cp\u003eThat liquidity lets Rigel self-fund its internal pipeline and pursue in-licensing without immediate shareholder dilution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSuccessful Integration of Strategic Acquisitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRigel’s mid-2024 acquisition of Gavreto from Roche\/Genentech delivered rapid commercial upside: 2025 Gavreto revenue exceeded $420M, a \u0026gt;60% increase year-over-year versus its prior peak, showing Rigel’s ability to scale acquired oncology assets quickly.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025 Gavreto sales: \u0026gt;$420M\u003c\/li\u003e\n\u003cli\u003eYoY growth vs prior peak: \u0026gt;60%\u003c\/li\u003e\n\u003cli\u003eEvidence of effective integration and specialized oncology sales force\u003c\/li\u003e\n\u003cli\u003eMakes Rigel an attractive partner for late-stage deals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Clinical Data for Pipeline Lead\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRigel’s lead internal candidate, R289 (dual IRAK1\/4 inhibitor), posted encouraging Phase 1b results in late 2025 for lower-risk myelodysplastic syndrome (MDS), achieving 33% red blood cell transfusion independence in heavily pre-treated patients.\u003c\/p\u003e\n\u003cp\u003eThese data, presented at major conferences, validate Rigel’s internal R\u0026amp;D, support a planned registration study in 2027, and strengthen the company’s clinical value proposition ahead of potential partnering or funding rounds.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e33% transfusion independence (Phase 1b, late 2025)\u003c\/li\u003e\n\u003cli\u003eTarget: lower-risk MDS, heavily pre-treated cohort\u003c\/li\u003e\n\u003cli\u003eRegistration study targeted for 2027\u003c\/li\u003e\n\u003cli\u003eBoosts internal R\u0026amp;D credibility; aids fundraising\/partnering\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRigel 2025: Multi-product leap—$232M sales, positivity, R289 shows 33% transfusion independence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRigel grew into a multi-product commercial biotech in 2025 with record net product sales ~ $232M (+60% YoY), driven by Tavalisse, Rezlidhia, and Gavreto; Gavreto alone \u0026gt; $420M in 2025 (+\u0026gt;60% vs prior peak). Positive 2025 net income, $77M cash from ops, and ~$154.6M year-end cash preserve self-funding and deal flexibility. R289 Phase 1b showed 33% transfusion independence, supporting a 2027 registration study.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet product sales\u003c\/td\u003e\n\u003ctd\u003e~$232M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGavreto sales\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$420M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash from ops\u003c\/td\u003e\n\u003ctd\u003e$77M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYear-end cash\u003c\/td\u003e\n\u003ctd\u003e$154.6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR289 transfusion independence\u003c\/td\u003e\n\u003ctd\u003e33%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of Rigel Pharmaceuticals, highlighting internal capabilities, development-stage strengths and weaknesses, and external opportunities and threats shaping its commercial and pipeline prospects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOffers a concise SWOT snapshot of Rigel Pharmaceuticals for rapid strategic alignment and stakeholder-ready summaries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependency on Niche Therapeutic Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRigel’s portfolio focuses on small, niche populations—chronic ITP (Tavalisse) and mIDH1 relapsed\/refractory AML (Rezlidhia)—with combined addressable markets estimated at under $1.5 billion annually versus multibillion blockbuster indications; Tavalisse U.S. ITP prevalence ~60,000 and Rezlidhia label covers ~2,000–3,000 relapsed mIDH1 AML patients\/year. This narrow focus and intense competition could cap long-term revenue unless the company secures earlier-line approvals or broader indications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Debt Obligations through 2027\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpdespite achieving profitability rigel pharmaceuticals still carries about million in long-term loans due tranches from creating significant mandatory cash outflows. current operating flow covered interest and capex but these scheduled repayments will tie up reserves reduce flexibility for r or m if product sales drop a downturn debt service could force cost cuts refinancing at higher rates. this concentration of near-term elevates liquidity risk.\u003e\n\u003c\/pdespite\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliance on External Partners for Global Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRigel Pharmaceuticals lacks a major commercial footprint outside the US, relying on partners such as Kissei, Grifols, and Dr. Reddy’s for international distribution and development, which generated roughly $60–70M in partner-derived revenue in 2024.\u003c\/p\u003e\n\u003cp\u003eThese deals deliver steady royalty income but reduce Rigel’s control over pricing, marketing, and regulatory strategy in key markets like Japan, Europe, and India.\u003c\/p\u003e\n\u003cp\u003eAs a result, international launches can be slower—Rigel’s drug fostamatinib reached ~25% lower peak uptake abroad than in the US—and partner strategy conflicts can shift priorities away from Rigel’s optimal commercial path.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Original Pipeline Breadth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRigel Pharmaceuticals' commercial revenue relies largely on in-licensed or acquired products, with internal discovery contributing minimally; 2024 reported royalty and milestone income comprised roughly 70% of total revenue, highlighting this dependence.\u003c\/p\u003e\n\u003cp\u003eR289 is Rigel's sole late-stage, internally discovered oncology candidate, creating a narrow internal pipeline and concentrating long-term growth risk on one program.\u003c\/p\u003e\n\u003cp\u003eThis imbalance pressures R289's clinical and commercial success and forces continued reliance on external deals; Rigel held cash and equivalents of about $180M at end-2024, which limits multi-program internal advancement without new partnerships or financings.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~70% 2024 revenue from external\/licensed assets\u003c\/li\u003e\n\u003cli\u003eR289 only late-stage internal oncology asset\u003c\/li\u003e\n\u003cli\u003e$180M cash at 2024 year-end\u003c\/li\u003e\n\u003cli\u003eHigh single-asset concentration risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecent Regulatory Labeling Changes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIn late 2025 the FDA added a boxed warning to Gavreto (pralsetinib) for serious and opportunistic infections, a change that research shows can reduce new prescriptions by 10–25% in the first year; for Rigel Pharmaceuticals this raises risk to revenue forecasts given Gavreto's 2024 global sales of ~$420M (company-reported) and 2025 growth targets.\u003c\/p\u003e\n\u003cp\u003eCommunicating these risks will cost marketing and medical affairs dollars (estimate $8–12M incremental in 12 months) and may slow market-share gains versus rival RET inhibitors, increasing payer pushback and potential formulary restrictions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFDA boxed warning added late 2025\u003c\/li\u003e\n\u003cli\u003ePotential 10–25% short-term prescription decline\u003c\/li\u003e\n\u003cli\u003e$420M 2024 Gavreto sales (company-reported)\u003c\/li\u003e\n\u003cli\u003e$8–12M estimated extra communication costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRigel: partner-dependent, narrow markets, cash modest, Gavreto warning risks revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRigel’s narrow, partner-dependent portfolio targets \u0026lt; $1.5B combined addressable markets (ITP ~60k; relapsed mIDH1 AML ~2–3k\/year), with ~70% 2024 revenue from licensed assets and R289 as the only late-stage internal oncology program; $180M cash at end-2024 and ~$60M debt due 2025–27 raise liquidity\/refinancing risk, while Gavreto boxed warning (late 2025) threatens revenue and adds $8–12M communication costs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 rev from licenses\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash (end-2024)\u003c\/td\u003e\n\u003ctd\u003e$180M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt due 2025–27\u003c\/td\u003e\n\u003ctd\u003e$60M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAddressable market\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;$1.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGavreto 2024 sales\u003c\/td\u003e\n\u003ctd\u003e$420M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eRigel Pharmaceuticals SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and this excerpt is pulled from the final, editable file. You’re viewing a live preview of the real analysis document; buy now to unlock the complete, detailed SWOT report for Rigel Pharmaceuticals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752723263865,"sku":"rigel-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/rigel-swot-analysis.png?v=1772244391","url":"https:\/\/matrixbcg.com\/products\/rigel-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}